Skip to main content

PerkinElmer Reports Increased Revenues in Q4

NEW YORK, Jan. 28 (GenomeWeb News) – PerkinElmer today reported revenues of $432.6 million for the fourth quarter ended Dec. 28, 2003, up from $410 million for the same period in 2002.

The increase, which included a 6 percent boost from foreign currency exchange rate fluctuations, was driven by revenue growth in all segments, the company said in a statement.

The company had net income of $28 million for the quarter, compared to a loss of $2.6 million for the year-ago quarter. The company had net income of $52 million for the year, compared to a loss of $152 million for 2002.

PerkinElmer had research and development expenditures of $20 million for the fourth quarter, compared to $22 million for the year-ago period.

Cash and cash equivalents on hand at the end of the quarter totaled $191 million, compared to $131 million for the same period in 2002.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.